Divarasib Shows Superior Efficacy for KRAS G12C Lung Cancer

Investigational drug divarasib, a next-generation KRAS G12C inhibitor, demonstrated superior efficacy in the Phase III Krascendo 1 study for previously treated KRAS G12C-mutated non-small cell lung cancer patients. It significantly improved overall survival to approximately 18 months, compared to 12 months for standard-of-care inhibitors, and reduced disease progression risk by 44%. These findings, presented at the ESMO Congress and published in The New England Journal of Medicine, showed no new safety concerns.